Aurinia Pharmaceuticals Inc - Common Shares (AUPH) analyst actions
Rating and price-target actions on AUPH in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AUPH overview →
1 measured AUPH analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis | Press release | +1.18% | -1.46% |
Keep exploring
More AUPH: earnings → · SEC filings → · AUPH overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TETRALOGIC PHARMS CORP (TLOG) | 226 | +0.20% | 52% |
| Y-mAbs Therapeutics, Inc. (YMAB) | 226 | -0.20% | 39% |
| Cel-Sci Corporation (CVM) | 224 | -0.54% | 37% |
| OraSure Technologies, Inc. (OSUR) | 224 | -0.17% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.